Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
An Open Label, Randomised, Single Dose, Three-way Crossover Study to Investigate the Relative Bioavailability of Two Different Formulations of GSK163090 and the Effect of Food on the Pharmacokinetics of a Tablet Formulation in Healthy Male and Female Volunteers
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Nordrhein-Westfalen
-
Neuss, Nordrhein-Westfalen, Duitsland, 41460
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Healthy male or female subjects between the ages of 18 and 55 years inclusive.
- If female, the subject is eligible to enter and participate in this study if she is not lactating and is of Non-childbearing potential or
- Child-bearing potential, has a negative pregnancy test at both screen and baseline and agrees to adequate contraception:
- Body weight ≥ 50 kg and body mass index (BMI) between 18.5 - 29.9 kg/m2 inclusive.
- Capable of giving informed consent and can comply with the study requirements and timetable.
- Self-administered Beck Depression Inventory II scale total score no greater than 9, and suicide question score of zero.
- The subject must be able to read, comprehend and record information.
- A signed and dated written informed consent is obtained from the subject.
- Non-smoker (abstinence from smoking for at least 6 months before the start of the study).
- Agrees to abstain from ingesting caffeine or xanthine-containing products for 24 hours prior to the start of dosing until collection of the final pharmacokinetic sample.
- Agree to abstain from alcohol for 24 hours prior to the start of dosing until collection of the final pharmacokinetic sample
Exclusion Criteria:
- As a result of any of the medical interview, physical examination or screening investigations the physician responsible considers the subject unfit for the study.
- The subject has a history of a drug or other allergy which in the opinion of the physician responsible contraindicates their participation in the study.
- The subject is currently participating or has participated in a clinical trial with a new chemical entity during the previous 4 months or any other trial during the previous 3 months.
- The subject has a screening ECG with values outside of protocoled ranges
- The subject has a pulse rate <45 or >100 bpm and a systolic blood pressure >150 and <90 and a diastolic blood pressure >90 and <50.
- History of long QT syndrome (personal or family) or other cardiac conduction disorder, or other clinically significant cardiac disease.
- The subject has liver function tests (LFT) elevated >1.5 times above the reference range at pre-study screening that remain elevated with a repeat LFT.
- Any other clinically significant laboratory abnormality.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety.
- Abuse of alcohol defined as an average weekly intake of greater than 21 units for males and 14 units for females or an average daily intake of greater than 3 units for males and 2 units for females. 1 unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.
- Consumption of grapefruit juice or grapefruit within 7 days prior to the first dose of study medication until collection of the last PK sample.
- The subject is unable to abstain from strenuous physical activity for 48 h prior to screening and follow up and for 48 h prior to and 48 h after each treatment period.
- Where participation in study would result in donation of blood in excess of 500 mL within a 90 day period
- An unwillingness of male subjects to abstain from, or use adequate contraception during, sexual intercourse with pregnant or lactating women from the time of the first dose of study medication until 90 days following administration of the last dose of study medication OR An unwillingness of the male subject to use a adequate contraception in addition to having their female partner use another form of contraception if the woman could become pregnant from the time of the first dose of study medication until 90 days following administration of the last dose of study medication.
- Current or recent (within one year) gastrointestinal disease; a history of malabsorption, esophageal reflux, irritable bowel syndrome; frequent (more than once a week) occurrence of heartburn; or any surgical intervention (e.g., cholecystectomy) which would be expected to influence the absorption of drugs.
- The subject has a history of psychiatric illness
- Any history of suicidal attempts or behavior.
- The subject has tested positive for hepatitis C antibody or hepatitis B surface antigen.
- The subject has tested positive for HIV.
- The subject has a past history of drug abuse or has tested positive for urine drugs of abuse at pre-study screening.
- The subject has any history of serotonin syndrome.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Sequence ABC
Subjects will be randomized to sequence ABC, where A=1 milligram (mg) GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed.
In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
|
GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 milliliters (mL) of water.
Andere namen:
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 mL of water.
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
|
|
Experimenteel: Sequence ACB
Subjects will be randomized to sequence ACB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed.
In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
|
GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 milliliters (mL) of water.
Andere namen:
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 mL of water.
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
|
|
Experimenteel: Sequence BAC
Subjects will be randomized to sequence BAC, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed.
In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
|
GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 milliliters (mL) of water.
Andere namen:
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 mL of water.
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
|
|
Experimenteel: Sequence BCA
Subjects will be randomized to sequence BCA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed.
In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
|
GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 milliliters (mL) of water.
Andere namen:
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 mL of water.
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
|
|
Experimenteel: Sequence CAB
Subjects will be randomized to sequence CAB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed.
In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
|
GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 milliliters (mL) of water.
Andere namen:
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 mL of water.
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
|
|
Experimenteel: Sequence CBA
Subjects will be randomized to sequence CBA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed.
In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
|
GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 milliliters (mL) of water.
Andere namen:
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with approximately 240 mL of water.
GSK163090 will be available as 1 mg white coated round tablet.
Each subject will receive a single, oral dose of the study medication on the morning of Day 1.
The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Pharmacokinetic parameters for GSK163090. Pharmacokinetic blood samples will be collected up to 72 hours post-dose following each dosing session.
Tijdsspanne: 72 hours post-dose following each dosing session.
|
72 hours post-dose following each dosing session.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Additional pharmacokinetic parameters, safety, and tolerability.
Tijdsspanne: 72 hours post-dose following each dosing session.
|
72 hours post-dose following each dosing session.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Werkelijk)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- 103268
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .